Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review
Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging
evidence suggests common mechanisms between cancer and cardiovascular disease …
evidence suggests common mechanisms between cancer and cardiovascular disease …
Cancer therapy–associated thrombosis
Patients with cancer have an increased risk of both arterial and venous thrombotic events
compared with the general population. Both the site and stage of cancer are known to …
compared with the general population. Both the site and stage of cancer are known to …
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
JE Cortes, DW Kim, J Pinilla-Ibarz… - Blood, The Journal …, 2018 - ashpublications.org
Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-
ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial …
ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial …
[HTML][HTML] Patients' acceptance of smartphone health technology for chronic disease management: a theoretical model and empirical test
K Dou, P Yu, N Deng, F Liu, YP Guan, Z Li… - JMIR mHealth and …, 2017 - mhealth.jmir.org
Background Chronic disease patients often face multiple challenges from difficult
comorbidities. Smartphone health technology can be used to help them manage their …
comorbidities. Smartphone health technology can be used to help them manage their …
[HTML][HTML] FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis
M Katoh - International journal of molecular medicine, 2016 - spandidos-publications.com
Abstract Fibroblast growth factor (FGF) 2, FGF4, FGF7 and FGF20 are representative
paracrine FGFs binding to heparan-sulfate proteoglycan and fibroblast growth factor …
paracrine FGFs binding to heparan-sulfate proteoglycan and fibroblast growth factor …
Vascular toxic effects of cancer therapies
J Herrmann - Nature Reviews Cardiology, 2020 - nature.com
Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among
these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the …
these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the …
First-line imatinib vs second-and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia
(CML), improves overall survival (OS), but the introduction of newer TKIs requires the …
(CML), improves overall survival (OS), but the introduction of newer TKIs requires the …
[HTML][HTML] High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
D Cao, H Xu, X Xu, T Guo, W Ge - Oncoimmunology, 2019 - Taylor & Francis
The relation between tumor mutation burden (TMB) and outcome of cancer patients
receiving immunotherapy has been reported. This study aimed to evaluate the prognostic …
receiving immunotherapy has been reported. This study aimed to evaluate the prognostic …
How I treat chronic myeloid leukemia in children and adolescents
N Hijiya, M Suttorp - Blood, The Journal of the American Society …, 2019 - ashpublications.org
Evidence-based recommendations have been established for treatment of chronic myeloid
leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this …
leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this …
[HTML][HTML] Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients
DJ Dorer, RK Knickerbocker, M Baccarani, JE Cortes… - Leukemia research, 2016 - Elsevier
Ponatinib is approved for adults with refractory chronic myeloid leukemia or Philadelphia
chromosome–positive acute lymphoblastic leukemia, including those with the T315I BCR …
chromosome–positive acute lymphoblastic leukemia, including those with the T315I BCR …